Dyslipidemia - Titration versus Combination Therapy

Datamonitor estimates that there are 307m people in the seven major markets with total cholesterol >200mg/dL and this is set to rise to 328m in 2011. However, despite this vast potential population, low diagnosis rates, the launch of generic statins and the maturing of the market mean that it is becoming increasingly important for companies to target the under-treated dyslipidemia sub-populations. 

Scope

Examination of the dyslipidemia patient potential, detailing the current and future prevalence of high total cholesterol 

Determination of the use of anti-dyslipidemics in dyslipidemia sub-populations and assessment of how treatment differs between each population 

Assessment the current and future trends in the use of combination therapy and potential role and uptake of adjunctive therapies 

Identification of the awareness, perception and expected future prescribing rates for new agents, such as Zetia (ezetimibe) and Crestor (rosuvastatin) 

Report Highlights

Following recommendations from the American Diabetes Association, statins remain the first line therapy for diabetic dyslipidemia and findings from HPS and CARDS add to this evidence. However, some experts believe that results from DAIS and VA-HIT support the use of fibrates as the lipid-lowering agents of choice in diabetic dyslipidemics. 

Although the use of combination therapy varies considerably across the seven major markets, this treatment strategy is becoming increasingly more common as treatment guidelines recommend more aggressive therapy in order to achieve lower target cholesterol goals and physicians remain reluctant to titrate statin doses. 

For new anti-dyslipidemics to be successful, agents must have the potential to improve outcomes by improving efficacy, safety or both. Zetia and Crestor represent the newest therapies to be launched in the US and EU and, in general, the opinion leaders interviewed remain considerably more optimistic over the future uptake of Zetia than Crestor. 

Reasons to Purchase

Gain an independent view of the management of dyslipidemia and understand how physicians are influenced in their prescribing practices 

Identify and quantify the ‘difficult-to-treat’ dyslipidemic populations and understand the differential treatment of dyslipidemia sub-populations 

Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products 

January 2004 Pages: 392 

Publisher: Datamonitor Cardiovascular Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular_Reports_2004.html#a447